Bioequivalence study of dapagliflozin 10 mg tablet
Not Applicable
Recruiting
- Conditions
- ---.
- Registration Number
- IRCT20230222057495N18
- Lead Sponsor
- Viana Darou Sanat Pharmaceutical company
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Healthy volunteer between 18 and 55 years old.
Body mass index less than 30 kg per square meter.
All candidates must be non-smokers.
Exclusion Criteria
Blood pressure less than 90 on 60 mm Hg or more than 140 on 90 mm Hg.
Consumption of any drug, alcohol or tobacco within 2 weeks before receiving the drug.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie dapagliflozin's SGLT2 inhibition in glucose regulation?
How does Viana Darou Sanat's dapagliflozin 10 mg compare to AstraZeneca's in pharmacokinetic profiles for type 2 diabetes?
Which biomarkers correlate with dapagliflozin efficacy in SGLT2 inhibitor response prediction?
What adverse events are associated with dapagliflozin 10 mg tablets in healthy volunteers and how are they managed?
How do SGLT2 inhibitors like dapagliflozin compare to GLP-1 receptor agonists in type 2 diabetes treatment outcomes?